WHO is undertaking a consultative process to solicit inputs into a prioritization framework for the research and development (R&D) of malaria health products. A draft report “Analysis of Malaria R&D Priorities” identifies five key challenges that represent threats or barriers to achieving the WHO Global Technical Strategy for Malaria 2016–2030 goals. This early copy of the report is being shared at a time when WHO is exploring how best to guide and support the development of priority solutions to meet public health needs.
Another MESA grantee has finalised its projects and shared the findings: the MESA-funded IVERMAL Study, a randomised, double-blind, placebo-controlled trial conducted in Kenya and led by the Liverpool School of Tropical Medicine (LSTM) has produced new evidence that supports the use of ivermectin as a tool for malaria elimination.
More than 180 scientists, malaria programme managers and policy makers from around the world have come together through a consultative process to update the research agenda for malaria elimination and eradication, first produced in 2011. The outcome is a series of seven ‘malERA Refresh’ (malaria eradication research agenda) papers that have undergone expert peer review and will soon be published in an open access journal.
“As a researcher working in a country that has decided to take on the challenge of eliminating malaria, the knowledge in the paper is enriching”. This is how Sandra Chishimba chose her ‘Top Pick’ article for World Malaria Day 2017. MESA (Malaria Eradication Scientific Alliance) asked five experts what recent paper has helped them in their effort to outsmart malaria.